The Complex Regional Pain Syndrome Market is estimated to be valued at US$ 103.7 Mn in 2023 and is expected to exhibit a CAGR of 2.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Complex regional pain syndrome (CRPS), also known as reflex sympathetic dystrophy syndrome (RSDS), is a chronic pain condition that affects the central nervous system. It usually affects an arm or leg, and is frequently triggered by an injury, surgery, stroke or heart attack. The intense pain associated with CRPS can make even light contact with the affected limb feel intolerable. This condition reduces quality of life significantly and in some cases may lead to disability.

Market key trends:
Increasing incidences of injuries triggering CRPS is expected to drive the market growth over the forecast period. For instance, according to the United States Bone and Joint Initiative report 2020, over 30 million Americans suffer from osteoporosis related bone fractures each year. This number is expected to increase to over 50 million by 2040. There has also been a rise in spinal injuries and orthopedic surgeries, all of which increase the chances of developing CRPS. Furthermore, various product launches and advancements to provide more effective treatment options for CRPS is also expected to aid the market growth during the forecast period. In 2021, Boston Scientific Corporation launched the WaveWriter Alpha spinal cord stimulator to provide relief from debilitating chronic pain conditions like CRPS through neuromodulation therapy.

Porter's Analysis

Threat of new entrants: Low due to high capital requirements for R&D and manufacturing. Bargaining power of buyers: Moderate due to availability of alternative therapies.

Bargaining power of suppliers: Moderate due to presence of large players.

Threat of new substitutes: Low due to lack of novel treatment options.

Competitive rivalry: Intense competition among existing players to gain higher market share.

SWOT Analysis

Strengths: Large R&D investments and presence of major players.

Weaknesses: Lack of approved drugs and diagnosis challenges.

Opportunities: Growing geriatric population and increasing healthcare expenditure.

Threats: High treatment costs and side effects associated with existing therapies.

Key Takeaways

The Global Complex Regional Pain Syndrome Market Size is expected to witness high growth, exhibiting CAGR of 2.2% over the forecast period, due to increasing prevalence of musculoskeletal disorders and trauma injuries.

North America is expected to dominate the market over the forecast period due to growing prevalence of CRPS along with presence of major players and availability of advanced healthcare facilities in the region.

Key players operating in the Complex Regional Pain Syndrome market are Boston Scientific Corporation, GlaxoSmithKline plc., Johnson & Johnson, Viatris, Sanofi S.A, and Medtronic Plc. Boston Scientific Corporation holds significant share in the market owing to its diversified product portfolio for pain management therapies.

For More Insights, Read: https://www.newswirestats.com/complex-regional-pain-syndrome-market-demand-growth-and-regional-outlook-by-2030/